Last reviewed · How we verify

NCT05772481: TEPIREC

Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Status unknown Last updated 23 August 2023
What this trial tests

trial testing PET-MRI in Rectal Cancer in 50 participants. Status unknown.

Timeline
19 May 2023
Primary endpoint
19 September 2025
19 September 2025

Quick facts

Lead sponsorInstitut de cancérologie Strasbourg Europe
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date19 May 2023
Primary completion19 September 2025
Estimated completion19 September 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Institut de cancérologie Strasbourg Europe — full company profile →

Who can join

Adults 18 to 75, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PET-MRI

Trials testing the same drug.

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

Other Institut de cancérologie Strasbourg Europe trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05772481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing